Cargando…

Quantitative and Pathologist-Read comparison of the Heterogeneity of Programmed Death-Ligand 1(PD-L1) expression in Non-Small Cell Lung Cancer

PD-L1 is expressed in a percentage of lung cancer patients and those patients show increased likelihood of response to PD-1 axis therapies. However, the methods and assays for assessment of PD-L1 using immunohistochemistry are variable and PD-L1 expression appears to be highly heterogeneous. Here, w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rehman, Jamaal A., Han, Gang, Carvajal-Hausdorf, Daniel E., Wasserman, Brad E., Pelekanou, Vasiliki, Mani, Nikita L., McLaughlin, Joseph, Schalper, Kurt A., Rimm, David L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2016
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5334264/ https://www.ncbi.nlm.nih.gov/pubmed/27834350 http://dx.doi.org/10.1038/modpathol.2016.186

Ejemplares similares

Effect of neoadjuvant chemotherapy on tumor-infiltrating lymphocytes and PD-L1 expression in breast cancer and its clinical significance
por: Pelekanou, Vasiliki, et al.
Publicado: (2017)

Erratum to: Effect of neoadjuvant chemotherapy on tumor-infiltrating lymphocytes and PD-L1 expression in breast cancer and its clinical significance
por: Pelekanou, Vasiliki, et al.
Publicado: (2017)

Clinical significance of PD-L1 protein expression on tumor-associated macrophages in lung cancer
por: Schalper, Kurt Alex, et al.
Publicado: (2015)

Objective measurement and clinical significance of IDO1 protein in hormone receptor-positive breast cancer
por: Carvajal-Hausdorf, Daniel E., et al.
Publicado: (2017)

Association of B7-H4, PD-L1, and tumor infiltrating lymphocytes with outcomes in breast cancer
por: Altan, Mehmet, et al.
Publicado: (2018)

Expression and clinical significance of PD-L1, B7-H3, B7-H4 and TILs in human small cell lung Cancer (SCLC)
por: Carvajal-Hausdorf, Daniel, et al.
Publicado: (2019)

Nuclear IRF-1 expression as a mechanism to assess “Capability” to express PD-L1 and response to PD-1 therapy in metastatic melanoma
por: Smithy, James W., et al.
Publicado: (2017)

Quantitative Measurement of Cancer Tissue Biomarkers in the Lab and in the Clinic
por: Carvajal-Hausdorf, Daniel, et al.
Publicado: (2014)

CD68, CD163, and matrix metalloproteinase 9 (MMP-9) co-localization in breast tumor microenvironment predicts survival differently in ER-positive and -negative cancers
por: Pelekanou, Vasiliki, et al.
Publicado: (2018)

Objective, domain-specific HER2 measurement in uterine and ovarian serous carcinomas and its clinical significance
por: Carvajal-Hausdorf, Daniel E., et al.
Publicado: (2017)

Possible role of hemichannels in cancer
por: Schalper, Kurt A., et al.
Publicado: (2014)

PD-L1 expression and tumor-infiltrating lymphocytes: Revisiting the antitumor immune response potential in breast cancer
por: Schalper, Kurt A
Publicado: (2014)

PD−L1 immunostaining: what pathologists need to know
por: Akhtar, Mohammed, et al.
Publicado: (2021)

High Concordance of a Closed-System, RT-qPCR Breast Cancer Assay for HER2 mRNA, Compared to Clinically Determined Immunohistochemistry, Fluorescence in situ Hybridization, and Quantitative Immunofluorescence
por: Wasserman, Brad E., et al.
Publicado: (2017)

Correction: PD − L1 immunostaining: what pathologists need to know
por: Akhtar, Mohammed, et al.
Publicado: (2022)

An assessment of neuronal calcium sensor-1 and response to neoadjuvant chemotherapy in breast cancer patients
por: Moore, Lauren M., et al.
Publicado: (2018)

Quantitative assessment of the spatial heterogeneity of tumor-infiltrating lymphocytes in breast cancer
por: Mani, Nikita L., et al.
Publicado: (2016)

Atlas of PD-L1 for Pathologists: Indications, Scores, Diagnostic Platforms and Reporting Systems
por: Marletta, Stefano, et al.
Publicado: (2022)

Automated measurement of estrogen receptor in breast cancer: a comparison of fluorescent and chromogenic methods of measurement
por: Zarrella, Elizabeth, et al.
Publicado: (2016)

Macrodissection prior to Closed System RT-qPCR is not necessary for Estrogen Receptor and HER2 Concordance with IHC/FISH in Breast Cancer
por: Gupta, Swati, et al.
Publicado: (2018)

Standardization of PD-L1 immunohistochemistry
por: Martinez-Morilla, Sandra, et al.
Publicado: (2021)

The Pathologist as Poet
por: Domen, Ronald E.
Publicado: (2016)

PD-L1 testing, fit for routine evaluation? From a pathologist’s point of view
por: Hutarew, Georg
Publicado: (2016)

Fit-For-Purpose PD-L1 Biomarker Testing For Patient Selection in Immuno-Oncology: Guidelines For Clinical Laboratories From the Canadian Association of Pathologists-Association Canadienne Des Pathologistes (CAP-ACP)
por: Cheung, Carol C., et al.
Publicado: (2019)

Global Recognition of Qualified Toxicologic Pathologists: Credential Review as a Potential Route for Recognizing the Proficiency of Pathologists Involved in Regulatory-type Nonclinical Studies
por: Ettlin, Robert A., et al.
Publicado: (2009)

The Value of the Pathologist to the Surgeon
por: Davis, E. C.
Publicado: (1911)

The Challenge to the Pathologist of PD-L1 Expression in Tumor Cells of Non-Small-Cell Lung Cancer—An Overview
por: Jöhrens, Korinna, et al.
Publicado: (2021)

Role of tumor infiltrating lymphocytes and spatial immune heterogeneity in sensitivity to PD-1 axis blockers in non-small cell lung cancer
por: Lopez de Rodas, Miguel, et al.
Publicado: (2022)

Lymph node retrieval in radical gastrectomy: the pathologist alone or the surgeon-pathologist team?
por: Lino-Silva, Leonardo S., et al.
Publicado: (2021)

Problems for Pathologists
Publicado: (1876)

To be or not to be an oral pathologist
por: Ramesh, V
Publicado: (2019)

Pathologists’ Fees
Publicado: (1885)

HIMSS10 – Perspectives from a newcomer pathologist and a seasoned attendee pathologist: Pathologists should attend!
por: Carter, Alexis B., et al.
Publicado: (2010)

Review by urological pathologists improves the accuracy of Gleason grading by general pathologists
por: Nakai, Yasushi, et al.
Publicado: (2015)

Genomic and Immune Profiling of a Patient With Triple-Negative Breast Cancer That Progressed During Neoadjuvant Chemotherapy Plus PD-L1 Blockade
por: Casadevall, David, et al.
Publicado: (2019)

Immunological Differences Between Immune-Rich Estrogen Receptor–Positive and Immune-Rich Triple-Negative Breast Cancers
por: O’Meara, Tess, et al.
Publicado: (2020)

Association of Clinical Pathologists
Publicado: (2002)

The Relationship of the Pathologist to the Surgeon
Publicado: (1905)

Pathologist to the Edinburgh Infirmary
Publicado: (1902)

Reading the tea leaves: Dead transposon copies reveal novel host and transposon biology
por: McLaughlin, Richard N.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_2o7mkta23re3ja1am4po69lkso